Loading...

News

Apellis Pharmaceuticals news, articles and events.
Home / News
December 20, 2016 - Apellis Announces FDA Fast Track Designation for APL-2 in PNH
LOUISVILLE, Ky., December 20, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the development program for APL-2, a complement C3 inhibitor, in the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), who continue to experience hemolysis and require RBC transfusions despite receiving therapy with eculizumab. PNH is a rare, acquired, potentially life-threatening disease characterized by complement-mediated hemolytic anemia. Read More
December 2, 2016 - Apellis Reports Positive Interim Results from Phase Ib Clinical Trials of APL-2 in PNH
LOUISVILLE, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim results from two ongoing Phase Ib open-label, dose-escalation clinical trials of APL-2, a complement C3 inhibitor, in paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, acquired, potentially life-threatening disease characterized by complement-mediated hemolytic anemia. Read More
November 21, 2016 - Apellis to Present Safety and Efficacy Data from Clinical Trials of APL-2 in PNH at December Scientific Meetings
LOUISVILLE, Ky., November 21, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, announced today it will present data from Phase 1 clinical trials of APL-2 in paroxysmal nocturnal hemoglobinuria (PNH) at two scientific meetings in December in San Diego. PNH is a rare, acquired, potentially life-threatening disease characterized by complement-mediated hemolytic anemia. Unlike other complement inhibitors, APL-2 targets C3, blocking all three activation pathways of the complement system, which may provide a more effective treatment approach than existing therapies. Read More
October 7, 2016 - Apellis to participate in a webcast on innovating for ophthalmic diseases
Cedric Francois, MD, PhD, Co-founder & CEO/President of Apellis Pharmaceuticals, Inc. will participate in a BioPharma Dealmakers webcast, sponsored in part by Apellis, featuring three companies innovating in therapies for eye disorders. The webcast, part of the BioPharma Dealmakers series, is scheduled for 10:00 am ET on October 20th. Read More
Webcast Registration
August 8, 2016 - Apellis Pharmaceuticals Announces Appointment of Dr. Robert Kim as Chief Medical Officer
Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the expansion of its executive team with the addition of Dr. Robert Kim as its Chief Medical Officer. Dr. Kim will help the company optimize its drug development strategy as its clinical programs progress toward late stage clinical testing.
"We are delighted to welcome Dr. Kim to Apellis. Bob is an experienced clinical drug developer whose deep knowledge and experience will help us prepare for our confirmatory trials in geography atrophy and the further expansion of our exciting clinical pipeline centered on the inhibition of complement factor C3," said Cedric Francois, CEO of Apellis Pharmaceuticals. Read More
June 23, 2016 - Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor
Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2. The trials were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous injection in healthy adult volunteers. Read More
Monographic Special Issue: Oligos & Peptides - Chimica Oggi-Chemistry Today - vol. 34(2) March/April 2016 – pp. 34
Small peptides for inhibition of central component of immunity: the complement system Read Article
March 24, 2016 - OIS Podcast | Can Apellis Find a way to Inhibit the Complement System & Treat Intermediate AMD?
Clinical trials of complement inhibitors recently have produced some disappointing results, but Apellis remains committed to demonstrating its own inhibitor can help bring relief to people battling geographic atrophy and AMD. Listen Now
February 12, 2016 - Apellis Completes $47 Million Series D Financing
Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital. The proceeds of the financing will be used to further advance clinical trials in the Company's ongoing complement immunotherapy programs, including paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA), an advanced form of dry type age-related macular degeneration (AMD), as well as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Read More
July 15, 2015 - Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board
Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the formation of a Scientific Advisory Board (SAB) comprised of physicians and scientists recognized as key opinion leaders in the areas of immunology, pulmonology, ophthalmology and hematology. The SAB's mission will be to provide valuable scientific and clinical insights, along with strategic guidance in decision-making, as the Company seeks to advance its drugs through clinical trials. Read More
March, 2015 - Therapeutic Thought - European Pharmaceutical Contractor
With most therapies being essentially symptomatic, the industry should look to immunotherapy to transform the management of autoimmunity. This approach is currently the focus in oncology pipelines, but hesitation remains due to its history and complexity Read Full Article
February 10, 2015 - Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2 in patients suffering from age-related macular degeneration (AMD).

The trial, labeled ASAP II, will focus on establishing safety of intravitreal injections of APL-2 and will be conducted in patients afflicted with wet AMD at multiple sites in the United States and Australia. Apellis plans to follow ASAP II with a larger Phase II trial in patients with geographic atrophy (the advanced stage of dry AMD) in the late spring of 2015. Read More
December 2, 2014 - Apellis Pharmaceuticals Raises $33M to Fund its Complement Immunotherapy Programs
Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock. The financing was led by Morningside Ventures and AJU IB Investment Co., Ltd. with Epidarex Ventures participating with follow-on funding. The proceeds will be used to fund three new complement immunotherapy programs entering clinical proof-of-concept stage. Read More
November 20, 2014 - Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals.
Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration (dry AMD). Read More
August 14, 2011 - How to launch a WONDER DRUG - The Courier Journal
Two years ago, in one of the biggest successes ever for Louisville’s young life-sciences industry, Potentia Pharmaceuticals sold a potentially groundbreaking vision drug to Alcon, the world’s largest eye-care company. Now Potentia’s two main officers and their new company, Apellis Pharmaceuticals, are using the scientific concept behind that drug to develop a medication for two lung ailments — asthma and chronic obstructive pulmonary disease Read Full Article